This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Laura Labeots
Partner at Lathrop GPM

Profile

For the past 25 years, Dr. Laura Labeots has helped companies develop and defend their Intellectual Property portfolios. She has a Ph.D.in Organic Chemistry from Northwestern University and did postdoctoral studies at the University of Chicago where later she became a Research Faculty Member. Her legal practice includes patent drafting and prosecution, litigation, opinion work (freedom-to-operate, patentability, invalidity, and infringement analyses), due diligence, licensing, trade secrets, trademark prosecution and litigation, and inter partes review proceedings before the U.S. Patent and Trademark Office.

Laura partners with companies to develop effective patent strategies on a wide range of matters including genetic testing, diagnostics, disease detection, vaccines, antibodies, nucleic acids, siRNA, miRNA, CRISPR, antisense oligonucleotides, RNAi, stem cells, pharmaceuticals, nanotechnology, chemical synthesis, polymeric materials, nutrition, agriculture/plants, veterinary medicine, orthopedic/dental/medical devices, light-shaping diffusers, holographic components, geotextiles, tools, and instrumentation.  In addition, she advises companies on issues relating to subject matter eligibility for nucleic acid-based inventions, genetics, and personalized medicine patents.

Some of the pharmaceutical agents that Laura has worked on include these: metastasis inhibitors, antifungal antibiotics, anticoagulants, macrolides, rifamycin antibiotics, proton pump inhibitors, reverse transcriptase inhibitors, anticonvulsants, estrogen receptor antagonists, antipsychotics, topical analgesics, appetite stimulants, attention deficit hyperactivity disorder modulators, acetylcholinesterase inhibitors, atypical antibiotics, dopamine agonists and psychostimulants.

Agenda Sessions

  • Strategies for Developing Robust Nucleic Acid Patent Portfolios

    7:45am